Onset: Slow. Unlike adaptogens with acute effects (rhodiola, theanine), maca is a slow-build compound. Most positive RCTs require 8–12 weeks at 1.5–3 g/day to read effect. Skipping the loading period is the #1 reason people report "didn't notice anything" — they took it for 2 weeks and quit.

Peak / steady-state: After ~8 weeks, sustained subjective improvement in libido (most commonly reported), mood/energy (secondary), and for menopausal women, hot flash frequency and intensity. Effect size is modest — users describe "noticeable but not dramatic," "wife-detected" libido improvement, "more interested in sex without thinking about it." Not euphoric, not stimulant-like.

Taper: Effects fade gradually over 2–4 weeks after stopping. No withdrawal syndrome, no rebound.

Characteristic effects:

• Increased baseline libido / sexual interest (the primary signal in RCT data and community reports)
• Mild energy improvement — not stimulant-like; more "absence of fatigue" than activation
• Mood elevation in a subset of users (~25-30% in community data)
• Some users report improved exercise volume tolerance, especially over 4-8 weeks of dosing
• Subjective stress resilience improvement is reported but poorly substantiated in trials

No-effect responders: A significant minority (~30-40% based on community data and trial drop-out reasoning) report no perceptible effect. Likely causes: low-macamide commercial product (especially Chinese imitation maca or raw uncolored "maca powder" without phenotype specification), insufficient duration (<8 weeks), or genuine individual non-response.

Negative subjective responders: Community data flags anxiety (~6.5% of reports), digestive upset (~5.8%), and insomnia (~4%) as the most common adverse subjective experiences. These are typically dose-related and resolve at lower doses or with gelatinized product.

Honest variability: Maca is one of the more variable supplements in subjective response — the combination of phenotype confusion, sourcing variability, slow onset, and modest effect size means that any individual's experience is heavily dependent on which product they bought and how long they committed. RCT data shows real signal; individual user experience is much noisier.

• Tolerance: Not formally demonstrated. Anecdotal community reports of "effect fades over 3-6 months" but RCT data through 4 months shows sustained effects (Gonzales 2001, Meissner 2006).
• Cycling: Not required pharmacologically. Many users continue indefinitely without issue. If concerned about adaptation, a "5 days on, 2 off" pattern or 2 months on / 2 weeks off is reasonable but not evidence-based — more pattern-of-mind than pharmacology.
• Long-term safety: Andean populations consume maca as a food at much higher doses (10-20 g/day) for lifetime exposure with no documented long-term adverse pattern. This is one of the strongest food-safety endorsements in the supplement world.
• Discontinuation: Effects fade over 2-4 weeks. No withdrawal, no rebound.

Synergistic with

• ashwagandha — community top-3 combo (168 co-mentions). Different mechanism (HPA-axis adaptogen, GABAergic, mild T-supporting in deficient men). Combined effect: stress + libido + energy axis. Reasonable stack for partnered V5 add.
• zinc — top community combo (177 co-mentions). Zinc directly supports T and sperm quality, complementing maca's CNS-mediated libido effect. Especially useful if zinc-deficient at baseline. Already in V4 (or default men's multi).
• tongkat-ali (eurycoma longifolia) — top-7 combo (133 co-mentions). Eurycoma activates the testicular T pathway directly via Leydig cell stimulation + SHBG modulation. Combining maca (CNS-libido, no T-effect) with tongkat (T-pathway, anabolic-leaning) covers both routes for libido restoration.
• mucuna pruriens — L-DOPA precursor. Theoretical synergy with maca's mild monoaminergic effect on libido and motivation.
• cocoa / dark chocolate — community anecdote (Discord block). Cocoa contains N-acylethanolamines and PEA, which compete for FAAH degradation. Combined with macamide FAAH inhibition, theoretical endocannabinoid synergy. Plus palatability — maca + cocoa is a traditional Andean preparation.
• rhodiola, ginseng (panax) — adaptogen stack — overlapping but non-redundant mechanisms.
• vitamin D3, omega-3 — top-5 community combos (170, 162). Background nutritional support; not pharmacodynamically synergistic but reflect a stack archetype focused on male hormonal/sexual health.

Avoid stacking with

• Cruciferous high-volume goitrogenic stack (raw kale juice + raw broccoli daily) + raw maca + iodine-deficient diet — additive goitrogen load. Either gelatinize the maca, eat cooked crucifers, or supplement iodine.
• Levothyroxine + raw maca on empty stomach — theoretical absorption interference (cruciferous goitrogens binding levothyroxine). Take 2+ hours apart if both required.
• Lithium — theoretical (limited data on cruciferous effects on lithium clearance). Probably moot at typical doses.

Neutral / safe co-administration

• All standard nootropic stacks (modafinil, racetams, choline donors, NSI-189, etc.) — no documented interactions.
• All V4 baseline supplements (magnesium, NAC, citicoline, PS, DHA, curcumin, theanine, glycine, D3/K2, beta-alanine, vitamin C) — neutral.
• Creatine — neutral.
• Most peptides (BPC-157, TB-500, Semax, Selank) — neutral.
• Coffee / caffeine — neutral (community top-8 combo, 121 co-mentions).

Maca's metabolic profile:

• Maca is a food-class supplement; pharmacokinetic data on macamides is limited.
• Macamides are absorbed orally; estimated bioavailability moderate.
• No significant CYP induction or inhibition documented at typical doses.

Clinically relevant interactions:

1. Levothyroxine / thyroid medications — theoretical. Raw cruciferous glucosinolates can transiently bind levothyroxine and reduce absorption. Mitigation: gelatinized maca, dose separation by 2+ hours.
2. SSRIs / SNRIs — no PK interaction; pharmacodynamic positive. Dording 2008 used maca specifically to rescue SSRI-induced sexual dysfunction — confirming it works on top of stable SSRI therapy without serotonin syndrome risk.
3. Hormone replacement therapy — no PK interaction; pharmacodynamic uncertain. Meissner 2006 demonstrated maca's symptomatic effect in menopausal women without exogenous HRT; co-use is not contraindicated but adds variability to clinical monitoring.
4. Tamoxifen / aromatase inhibitors — theoretical caution in breast cancer treatment. No direct data; cruciferous compounds have variable effects on estrogen metabolism (broccoli's I3C/DIM is sometimes recommended with tamoxifen by integrative oncologists). Discuss with oncology team.
5. Anticoagulants (warfarin) — theoretical. Cruciferous vegetable variability affects vitamin K intake; if eating maca powder at >5 g/day, modest vitamin K contribution. Monitor INR if introducing/stopping high-dose maca.
6. Lithium — theoretical, very weak. Probably not clinically significant at typical doses.

Practical: maca has no significant drug interactions at standard doses (1-3 g/day, gelatinized) in healthy populations. The main interaction concerns are thyroid-related and apply primarily to raw maca + iodine-deficient + hypothyroid combinations.

Limited PGx data exist for maca specifically. Inferred from mechanism:

• CYP polymorphisms — minor relevance. Macamide metabolism is not well characterized; no clear CYP-substrate liability.
• FAAH C385A (rs324420) polymorphism — common variant affecting endocannabinoid degradation. Carriers (A-allele) have lower FAAH activity → higher baseline anandamide → theoretically less responsive to additional FAAH inhibition from macamides. Speculative but mechanistically grounded; could explain some non-responder phenomena.
• Androgen receptor (CAG repeats) — relevant for general libido baseline but not for maca-specific response (maca doesn't act through androgen pathway).
• Estrogen receptor polymorphisms (ESR1, ESR2) — relevant for menopausal symptom variability; maca's menopausal symptom benefit may depend on individual ESR1/ESR2 status.
• HLA / immune polymorphisms — no documented maca hypersensitivity links.

Practical: No clinical pharmacogenomic testing changes maca decisions. 23andMe FAAH C385A status (when results arrive in June for this user) would be a tunable variable — A/A homozygotes may respond less to maca's FAAH-related effects. Not blocker-level data.

Sourcing key points: (1) Origin: Peru (Junin/Pasco/Andean, >4,000 m altitude) — avoid Chinese (Yunnan) maca. (2) Color: specify — black for male libido/sperm, red for menopause/prostate, yellow is commodity. (3) Processing: gelatinized for tolerance + lower goitrogen load. (4) Form: powder > capsule for cost and flexibility (earthy/malty flavor in smoothies, oatmeal, coffee). (5) Certification: USDA Organic + third-party heavy-metal testing (root crops accumulate cadmium/lead).

For this user (if/when attempting): Maca Team gelatinized black maca powder, 1.5 g/day × 8 weeks. ~$25 commitment, food-grade safety.

Baseline (pre-trial):

• Total testosterone, free testosterone (LC-MS/MS preferred — not immunoassay due to maca-related assay interference case report)
• LH, FSH, prolactin, estradiol
• TSH, free T4, free T3 (especially if any thyroid history)
• Sperm analysis if fertility-relevant (volume, count, motility, morphology)
• Subjective libido VAS (0-10 scale, baseline-week)
• Subjective energy VAS, mood VAS

Repeat at 8 and 12 weeks:

• Subjective VAS scores — primary efficacy readout
• T, LH, FSH (should NOT change — confirms identity)
• TSH (monitor for goitrogen effect, especially if running raw maca or >3 g/day)
• Sperm analysis at 16 weeks if fertility goal (sperm cycle ~74 days)

Discontinuation criteria:

• No subjective benefit by week 12 at 3 g/day → discontinue, save money
• TSH rise into hypothyroid range → discontinue or switch to gelatinized lower dose
• Significant subjective adverse effect (anxiety, insomnia, GI) → discontinue or lower dose
• Pregnancy → discontinue

Long-term (if continuing 6+ months):

• Annual TSH check
• Annual T panel — if claiming T improvement on maca, you're misattributing (lifestyle factor or another stack member is responsible)